IP Library › Granted Patent US 8,895,521
Granted Patent B2
US 8,895,521 · App. 11/579,518 · Granted Nov 25, 2014

Methods and compositions for the treatment of uveitis

Inventors: Dennis M. Klinman (Potomac, MD); Igal Gery (Bethesda, MD); Chiaki Fujimoto (North Bethesda, MD)
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
C12N15/117C12N2310/17C12N2310/18A61K31/7088A61K45/06C12N2310/315C12N2310/151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,895,521
App. No.
11/579,518
Granted
Nov 25, 2014
Kind
B2
Abstract

Pharmaceutical compositions are disclosed that are of use for the treatment of uveitis. These compositions include a suppressive oligonucleotide. These compositions including an immunosuppressive oligonucleotide can be used for the treatment of uveitis, including anterior, posterior, and diffuse uveitis.

Claims (19)

1. A method of reducing uveitis in a subject, comprising

selecting an isolated oligodeoxynucleotide consisting of the nucleic acid sequence set forth as SEQ ID NO: 2; and

systemically or intraocularly administering to the subject in need thereof a therapeutically effective amount of a composition comprising the selected isolated oligodeoxynucleotide and a pharmaceutically acceptable carrier to suppress production of interleukin (IL-4) and interferon gamma, and thereby reducing ocular inflammation in the subject.

2. The method of claim 1 , wherein the oligodeoxynucleotide is administered systemically.

3. The method of claim 1 , wherein the uveitis comprises anterior or posterior uveitis.

4. The method of claim 1 , wherein the uveitis comprises diffuse uveits.

5. The method of claim 1 , wherein the uveitis comprises at least one of cyclitis, pars planitis, chorioretinitis (inflammation of the choroid), iridocyclitis, or iritis.

6. The method of claim 1 , further comprising administering a therapeutically effective amount of an additional anti-inflammatory agent.

7. The method of claim 1 , further comprising administering a therapeutically effective amount of an additional non-nucleotide immunosuppressive agent.

8. The method of claim 1 , further comprising administering a therapeutically effective amount of an antibacterial or an antifungal agent.

9. The method of claim 1 , wherein the uveitis is a result of surgical or traumatic injury to the eye.

10. The method of claim 1 , wherein the uveitis is a result of an autoimmune disorder.

11. The method of claim 1 , wherein the uveitis is a result of an infection.

12. The method of claim 1 , wherein the composition is administered intraocularly by administering the therapeutically effective amount of the oligonucleotide topically to the eye.

13. The method of claim 1 , wherein the composition is administered intraocularly by intravitreal administration.

14. The method of claim 1 , wherein the composition is administered intraocularly by implantation.

15. The method of claim 1 , further comprising measuring the production of IL-4, interferon gamma or both by lymphocytes from the subject.

16. The method of claim 1 , wherein the oligodeoxynucleotide is modified to prevent degradation.

17. The method of claim 16 , wherein the oligodeoxynucleotide comprises a phosphodiester modification.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2006
From: KLINMAN, DENNIS M.; GERY, IGAL; FUJIMOTO, CHIAKI
To: GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE
Reel/Frame 018549/0787 →
Continuity (2)
Provisional Application 60569276 · May 6, 2004
Related Publication 20090082288A1 · Mar 26, 2009